The assessment of different risk classification systems for gastrointestinal stromal tumors (GISTs): the analytic results from the SEER database

References

• Steigen SE, Eide TJ. Trends in incidence and survival of mesenchymal neoplasm of the digestive tract within a defined population of northern Norway. Apmis. 2006;114:192–200.
   PubMed Web of Science ®Google Scholar
• Miettinen M, Lasota J. Gastrointestinal stromal tumors-definition, clinical, histological, immunohistochemical, and molecular genetic features and differential diagnosis. Virchows Arch. 2001;438:1–12.
   PubMed Web of Science ®Google Scholar
• Miettinen M, Lasota J. Gastrointestinal stromal tumors: pathology and prognosis at different sites. Semin Diagn Pathol. 2006;23:70–83.
   PubMed Web of Science ®Google Scholar
• Harlan LC, Eisenstein J, Russell MC, et al. Gastrointestinal stromal tumors: treatment patterns of a population-based sample. J Surg Oncol. 2015;111:702–707.
   PubMed Web of Science ®Google Scholar
• Hirota S, Isozaki K, Moriyama Y, et al. Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors. Science. 1998;279:577–580.
   PubMed Web of Science ®Google Scholar
• Kindblom LG, Remotti HE, Aldenborg F, et al. Gastrointestinal pacemaker cell tumor (GIPACT): gastrointestinal stromal tumors show phenotypic characteristics of the interstitial cells of Cajal. Am J Pathol. 1998;152:1259–1269.
   PubMed Web of Science ®Google Scholar
• Wozniak A, Floris G, Debiec-Rychter M, et al. Implications of mutational analysis for the management of patients with gastrointestinal stromal tumors and the application of targeted therapies. Cancer Invest. 2010;28:839–848.
   PubMed Web of Science ®Google Scholar
• Roggin KK, Posner MC. Modern treatment of gastric gastrointestinal stromal tumors. Wjg. 2012;18:6720–6728.
   PubMed Web of Science ®Google Scholar
• DeMatteo RP, Ballman KV, Antonescu CR, et al. Long-term results of adjuvant imatinib mesylate in localized, high-risk, primary gastrointestinal stromal tumor: ACOSOG Z9000 (Alliance) intergroup phase 2 trial. Ann Surg. 2013;258:422–429.
   PubMed Web of Science ®Google Scholar
• Dematteo RP, Ballman KV, Antonescu CR, et al. Adjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour: a randomised, double-blind, placebo-controlled trial. Lancet. 2009;373:1097–1104.
   PubMed Web of Science ®Google Scholar
• Joensuu H, Vehtari A, Riihimaki J, et al. Risk of recurrence of gastrointestinal stromal tumour after surgery: an analysis of pooled population-based cohorts. Lancet Oncol. 2012;13:265–274.
   PubMed Web of Science ®Google Scholar
• Nishida T, Hirota S, Yanagisawa A, et al. Clinical practice guidelines for gastrointestinal stromal tumor (GIST) in Japan: English version. Int J Clin Oncol. 2008;13:416–430.
   PubMed Web of Science ®Google Scholar
• Fletcher CD, Berman JJ, Corless C, et al. Diagnosis of gastrointestinal stromal tumors: a consensus approach. Int J Surg Pathol. 2002;10:81–89.
   PubMed Web of Science ®Google Scholar
• Dematteo RP, Gold JS, Saran L, et al. Tumor mitotic rate, size, and location independently predict recurrence after resection of primary gastrointestinal stromal tumor (GIST). Cancer. 2008;112:608–615.
   PubMed Web of Science ®Google Scholar
• Hassan I, You YN, Shyyan R, et al. Surgically managed gastrointestinal stromal tumors: a comparative and prognostic analysis. Ann Surg Oncol. 2008;15:52–59.
   PubMed Web of Science ®Google Scholar
• Rutkowski P, Wozniak A, Dębiec-Rychter M, et al. Clinical utility of the new American Joint Committee on Cancer staging system for gastrointestinal stromal tumors: current overall survival after primary tumor resection. Cancer. 2011;117:4916–4924.
   PubMed Web of Science ®Google Scholar
• Hohenberger P, Ronellenfitsch U, Oladeji O, et al. Pattern of recurrence in patients with ruptured primary gastrointestinal stromal tumour. Br J Surg. 2010;97:1854–1859.
   PubMed Web of Science ®Google Scholar
• Takahashi T, Nakajima K, Nishitani A, et al. An enhanced risk-group stratification system for more practical prognostication of clinically malignant gastrointestinal stromal tumors. Int J Clin Oncol. 2007;12:369–374.
   PubMed Web of Science ®Google Scholar
• Joensuu H. Risk stratification of patients diagnosed with gastrointestinal stromal tumor. Hum Pathol. 2008;39:1411–1419.
   PubMed Web of Science ®Google Scholar
• Gold JS, Gonen M, Gutierrez A, et al. Development and validation of a prognostic nomogram for recurrence-free survival after complete surgical resection of localised primary gastrointestinal stromal tumour: a retrospective analysis. Lancet Oncol. 2009;10:1045–1052.
   PubMed Web of Science ®Google Scholar
• Bischof DA, Kim Y, Behman R, et al. A nomogram to predict disease-free survival after surgical resection of GIST. J Gastrointest Surg. 2014;18:2123–2129.
   PubMed Web of Science ®Google Scholar
• Rutkowski P, Nowecki ZI, Michej W, et al. Risk criteria and prognostic factors for predicting recurrences after resection of primary gastrointestinal stromal tumor. Ann Surg Oncol. 2007;14:2018–2027.
   PubMed Web of Science ®Google Scholar
• Goh BK, Chow PK, Yap WM, et al. Which is the optimal risk stratification system for surgically treated localized primary GIST? Comparison of three contemporary prognostic criteria in 171 tumors and a proposal for a modified Armed Forces Institute of Pathology risk criteria. Ann Surg Oncol. 2008;15:2153–2163.
   PubMed Web of Science ®Google Scholar
• Rutkowski P, Bylina E, Wozniak A, et al. Validation of the Joensuu risk criteria for primary resectable gastrointestinal stromal tumour - the impact of tumour rupture on patient outcomes. Eur J Surg Oncol. 2011;37:890–896.
   PubMed Web of Science ®Google Scholar
• Park CH, Kim GH, Lee BE, et al. Two staging systems for gastrointestinal stromal tumors in the stomach: which is better?. BMC Gastroenterol. 2017;17:141
   PubMed Web of Science ®Google Scholar
• Kim MC, Yook JH, Yang HK, et al. long-term surgical outcome of 1057 gastric gists according to 7th UICC/AJCC TNM system: multicenter observational study from Korea and Japan. Medicine (Baltimore). 2015;94:e1526.
   PubMed Web of Science ®Google Scholar
• Yanagimoto Y, Takahashi T, Muguruma K, et al. Re-appraisal of risk classifications for primary gastrointestinal stromal tumors (GISTs) after complete resection: indications for adjuvant therapy. Gastric Cancer. 2015;18:426–433.
   PubMed Web of Science ®Google Scholar
• Schmieder M, Henne-Bruns D, Mayer B, et al. comparison of different risk classification systems in 558 patients with gastrointestinal stromal tumors after R0-resection. Front Pharmacol. 2016;7:504.
   PubMed Web of Science ®Google Scholar
• Chok AY, Goh BK, Koh YX, et al. Validation of the MSKCC gastrointestinal stromal tumor nomogram and comparison with other prognostication systems: single-institution experience with 289 patients. Ann Surg Oncol. 2015;22:3597–3605.
   PubMed Web of Science ®Google Scholar
• Belfiori G, Sartelli M, Cardinali L, et al. Risk stratification systems for surgically treated localized primary Gastrointestinal Stromal Tumors (GIST). Review of literature and comparison of the three prognostic criteria: MSKCC Nomogramm, NIH-Fletcher and AFIP-Miettinen. Ann Ital Chir. 2015;86:219–227.
   PubMed Web of Science ®Google Scholar
• Racz JM, Brar SS, Cleghorn MC, et al. The accuracy of three predictive models in the evaluation of recurrence rates for gastrointestinal stromal tumors. J Surg Oncol. 2015;111:371–376.
   PubMed Web of Science ®Google Scholar
• Tanimine N, Tanabe K, Suzuki T, et al. Prognostic criteria in patients with gastrointestinal stromal tumors: a single center experience retrospective analysis. World J Surg Onc. 2012;10:43.
   PubMed Web of Science ®Google Scholar
• Joensuu H, Eriksson M, Sundby Hall K, et al. One vs three years of adjuvant imatinib for operable gastrointestinal stromal tumor: a randomized trial. Jama. 2012;307:1265–1272.
   PubMed Web of Science ®Google Scholar
• Joensuu H, Eriksson M, Sundby Hall K, et al. Adjuvant imatinib for high-risk gi stromal tumor: analysis of a randomized trial. J Clin Oncol. 2016;34:244–250.
   PubMed Web of Science ®Google Scholar
• Cohen MH, Johnson JR, Justice R, et al. Approval summary: imatinib mesylate for one or three years in the adjuvant treatment of gastrointestinal stromal tumors. Oncologist. 2012;17:992–997.
   PubMed Web of Science ®Google Scholar
• Lin JX, Chen QF, Zheng CH, et al. Is 3-years duration of adjuvant imatinib mesylate treatment sufficient for patients with high-risk gastrointestinal stromal tumor? A study based on long-term follow-up. J Cancer Res Clin Oncol. 2017;143:727–734.
   PubMed Web of Science ®Google Scholar
• Giuliano K, Nagarajan N, Canner J, et al. Gastric and small intestine gastrointestinal stromal tumors: do outcomes differ? J Surg Oncol. 2017;115:351–357.
   PubMed Web of Science ®Google Scholar
• Guller U, Tarantino I, Cerny T, et al. Revisiting a dogma: similar survival of patients with small bowel and gastric GIST. A population-based propensity score SEER analysis. Gastric Cancer. 2017;20:49–60.
   PubMed Web of Science ®Google Scholar
• Fero KE, Coe TM, Fanta PT, et al. Surgical management of adolescents and young adults with gastrointestinal stromal tumors: a us population-based analysis. JAMA Surg. 2017;152:443–451.
   PubMed Web of Science ®Google Scholar
• Kramer K, Knippschild U, Mayer B, et al. Impact of age and gender on tumor related prognosis in gastrointestinal stromal tumors (GIST). BMC Cancer. 2015;15:57.
   PubMed Web of Science ®Google Scholar
• Tran T, Davila JA, El-Serag HB. The epidemiology of malignant gastrointestinal stromal tumors: an analysis of 1,458 cases from 1992 to 2000. Am J Gastroenterol. 2005;100:162–168.
   PubMed Web of Science ®Google Scholar
• Fujimoto Y, Nakanishi Y, Yoshimura K, et al. Clinicopathologic study of primary malignant gastrointestinal stromal tumor of the stomach, with special reference to prognostic factors: analysis of results in 140 surgically resected patients. Gastric Cancer. 2003;6:39–48.
   PubMedGoogle Scholar